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a b s t r a c t
Objective: The purpose of this study was to evaluate the performance of a chemilumines-
cent immunoassay (CLIA) to detect anti-dsDNA antibodies, using the indirect immunofl uo-
rescence test (IIF) on Crithidia luciliae as a reference. 
Methods: The automation system demonstrated 81% effi ciency, 100% sensitivity and 82% 
specifi city according to the intrinsic validation process performed using 179 consecutive 
samples from 169 patients in the beginning of 2011. These patients were subsequently di-
vided into 3 groups according to the co-reactivity of anti-dsDNA results using the 2 meth-
ods (reactive, non-reactive and discrepant results). 
Results: Upon data analysis, 77% (129/169) of the tests were requested by rheumatologists, 
and 57% (97/169) of the samples were from lupus patients. Both the reactive and non-reac-
tive results of the CLIA were well defi ned and standardised, and automation reduced the 
manual labor required by 70% in a safe and high-quality manner. Furthermore, the high 
prevalence of patients with lupus and nephritis among the CLIA false-positive results cor-
roborates the hypothesis that the actual index of CLIA false positivity is lower than that 
initially found in this study. 
© 2013 Elsevier Editora Ltda. All rights reserved.
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Utilidade da triagem dos anticorpos anti-dsDNA por 
quimioluminescência, seguida de confi rmação por imunofl uorescência 
indireta
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r e s u m o
Objetivo: Avaliar o desempenho de um imunoensaio quimioluminescente (CLIA) para os 
anticorpos anti-dsDNA, utilizando como referência o teste de imunofl uorescência indireta 
(IFI) sobre Crithidia luciliae. 
Métodos: O sistema de automação foi previamente aprovado com 81% de efi ciência, 100% 
de sensibilidade e 82% de especifi cidade, por processo de validação intrínseca em 179 
amostras consecutivas de 169 pacientes no início de 2011. A seguir, esses pacientes foram 
subdivididos em três grupos de acordo com os resultados da pesquisa dos anticorpos anti-
-dsDNA nas duas metodologias (reagentes, não reagentes e resultados discrepantes). 
Resultados: Na análise dos dados: 1) 77% (129/169) dos exames haviam sido solicitados por 
médicos reumatologistas; 2) 57% (97/169) das amostras eram de pacientes lúpicos; 3) Os 
resultados de CLIA, reagentes e não reagentes, estavam bem defi nidos e padronizados; 4) 
A automação reduziu em 70% as passagens pela técnica manual com segurança e quali-
dade; 5) A alta prevalência de pacientes lúpicos e com nefrite entre os resultados de CLIA 
falso-positivos corrobora a hipótese de que o índice real de falsa positividade do CLIA seja 
menor que o encontrado inicialmente neste estudo.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
The study of anti-double-stranded DNA (anti-dsDNA) auto-
antibodies is useful for the diagnosis and management of 
systemic lupus erythematosus (SLE),1 especially in patients 
with lupus nephritis.2 Automated assays have been intro-
duced as a more rapid alternative for anti-dsDNA antibody 
screening in the major laboratories.3 Although radioimmu-
noassay tests are recognised as a more specifi c method, such 
tests are less commonly used because they require the use 
of radioactive material.4 Automated assays process large vol-
umes of clinical samples quickly and at lower cost than tra-
ditional methods.5,6 
The implementation of serological testing in a clinical pa-
thology laboratory requires an intrinsic validation process 
to evaluate test performance by comparison to a reference 
method, according to sensitivity, specifi city and effi ciency 
parameters. This validation process evaluates features of the 
new test rather than those of the population to which it is 
being applied, which enables the collection of consistent re-
sults that are independent of disease prevalence.7 These val-
idation methods may be approved for replacing techniques 
(change of reactive supplier), improving quality (an addition 
to the technique in use) and/or reducing laboratory operat-
ing costs. This type of analysis does not require approval 
of an ethics committee because the origin of the biological 
sample should not be disclosed. 
From 2002 to 2006, the prevalence of positive antinucle-
ar antibody (ANA)-Hep-2 test results at the Hospital Geral 
de Fortaleza (HGF) was studied. Among the 6,000 samples 
analysed, negative results were obtained in 84% of cases,8 
which justifi ed the performance of autoimmune screening 
tests using an automated method to reduce the test time 
and chance of human error resulting from the interface with 
the equipment.
The objective of this study was to analyse the perfor-
mance of a chemiluminescent immunoassay (CLIA) for the 
detection of anti-dsDNA antibodies, using the indirect im-
munofl uorescence assay (IFA) on Crithidia luciliae as a refer-
ence. Upon approval of an internal protocol of the Clinical 
Pathology Laboratory of HGF for the intrinsic validation of 
an automation system for screening ANA and anti-dsDNA 
antibodies, this project was developed to analyse medical 
records of the clinical samples studied. This study was ap-
proved by the Research Ethics Committee of HGF under pro-
tocol number 060705/11; all authors signed the trustee state-
ment and declared no confl icts of interest.
Materials and methods
Sample
From February to March 2011, serum samples sent to the 
HGF laboratory for the detection of anti-dsDNA antibodies 
were examined in the immunofl uorescence unit and subse-
quently forwarded to the automation unit. The tests were 
carried out independently by the two technical teams. The 
IFA results were released in a timely manner without detri-
ment to the patients. The intrinsic validation of the auto-
mation system was approved with 81% effi ciency (results in 
agreement with IFA), 100% sensitivity and 82% specifi city. 
Demographic (age and gender), epidemiological and clini-
cal (reason for the request, diagnoses, duration of symptoms 
and laboratory results) data for patients (n = 169) included in 
this study were obtained from the laboratory database and 
medical records after approval from the ethics committee.
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Anti-dsDNA antibody tests were requested in subsequent 
consultations for patients with discrepant results between 
the two methods during the CLIA validation period and were 
monitored for one year (March/11 to March/12), without in-
volvement of the study authors.
Laboratory analysis
Chemiluminescence assay (CLIA): LIAISON_dsDNA (DiaSo-
rin, Saluggia, Italy) is a CLIA that uses magnetic particles 
coated with a synthetic dsDNA oligonucleotide, which en-
sures the absence of contamination with histones and other 
nuclear proteins. A monoclonal antibody labelled with an 
isoluminol derivative is used as a conjugated antibody to 
detect IgG anti-dsDNA antibodies.5 All test procedures were 
performed automatically in a primary sample using the LI-
AISON® system. The reactivity pattern was defi ned by the 
manufacturer as non-reactive (< 20 IU/mL), in the grey zone 
(20-25 IU/mL) or reactive (> 25 IU/mL). 
Indirect immunofl uorescence assay (IFA): These tests 
were performed using the commercially available method 
(Euroimmun, Lubeck, Germany) according to the manufac-
turer’s technical recommendations. The sera were 1/10 di-
luted in phosphate-buffered saline solution and incubated 
on glass slides with the antigen substrate (Crithidia luciliae), 
where the anti-dsDNA antibodies present bind to the ki-
netoplast and are revealed by a specifi c fl uorescein isothio-
cyanate-labelled anti-gamma-globulin. Internal positive 
and negative controls were conducted in each test routine. 
Cell staining was examined using a fl uorescence micro-
scope (model Nikon YS2H) under 400x magnifi cation. Sera 
with positive results in the 1/10 screening were expressed in 
semiquantitative titres. 
Statistical analysis
The data were collected in a Microsoft Excel® spreadsheet. 
Sensitivity, specifi city and effi ciency tests were carried out 
for validation of the serological test using the analysis of 
anti-dsDNA antibodies by IFA as a reference test.
Results
The intrinsic evaluation was performed with 179 serum 
samples, which were analysed using both techniques. The 
CLIA was positive in 41 (23%) serum samples, negative in 
132 (74%) and indeterminate (grey area) in six samples (3%). 
The six indeterminate sera samples were grouped with the 
positive samples for comparing sensitivity, specifi city and 
effi ciency of the method compared to IFA. The comparison 
between the two methods revealed that 15 samples (8.4%) 
were positive in both techniques, 132 (73.7%) were double 
negative, 32 (17.9%) were false positive in CLIA, and none 
were false negative in CLIA, revealing a sensitivity of 100%, 
specifi city of 82% and an effi ciency of 81% for CLIA. After this 
analysis, the laboratory implemented screening of anti-dsD-
NA antibodies by automation, in which positive results were 
re-evaluated by IFA for confi rmation. In this new screening 
process, the manual phase was reduced by 74% (132/179) of 
the previous total test-bench effort, limiting the need for 
manual testing in each of the 4 tests previously performed 
using the IFA method.
The intrinsic evaluation (179 serum samples) comparing 
the CLIA and IFA methods involved 169 patients with eight 
duplicate sera and one triplicate sample. The CLIA results of 
multiple samples were negative in seven patients and dis-
crepant in one patient (32 and 13.8 IU/mL), with double serum 
samples positive in the patient with three anti-dsDNA anti-
body test requests over a 2-month period (154.6, 46 and 37.5 
IU/mL). All these sera samples were negative using the IFA 
method. An analysis of these results will be presented later.
The epidemiological and demographic characteristics of 
this patient sample are shown in Table 1. Patients were clas-
sifi ed according to the diagnoses in their medical records. 
One third of the sample (55 patients) comprised patients 
under diagnostic investigation due to clinical suspicion of 
SLE, where the test requests were made due to the presence 
Table 1 – Epidemiological characteristics of the sample 
(n = 169).
Clinical sample characteristics  n (%)
Gender  
Male 16 (9)
Female 153 (91)
Age range (years) (n = 166)a
Children (< 11 ) 3 (2%)
Adolescents (12 to 19) 20 (12%)
Adults  
20-29 54 (33%)
30-39 43 (26%)
40-49 28 (17%)
50-59 12 (7%)
60-69 6 (4%)
Clinic requesting test  
Rheumatology 123 (73%)
Medical clinic 19 (11%)
Nephrology 7 (4%)
Gynaecology/obstetrics 7 (4%)
Paediatric rheumatology 6 (4%)
Other clinicb 7 (4%)
Patient diagnosis  
SLE 92(54%)
SLE overlap syndrome 5 (3%)
Investigation of autoimmune diseasec 55 (33%)
Other autoimmune diseases 17 (10%)
Primary APLS 4
Rheumatoid arthritis 3
Vasculitis 2
Devic’s disease 2
Mixed connective tissue disease 1
Sjögren’s syndrome 1
Ankylosing spondylitis 1
Linear systemic sclerosis 1
Autoimmune thyroiditis 1
Multiple sclerosis 1
SLE, systemic lupus erythematosus; APLS, antiphospholipid 
antibody syndrome.
a Three patients did not have records and their ages were not 
mentioned in the laboratory records. 
b Emergency, endocrinology, neurology and ICU. 
c The patients without medical records (n = 3) were included in this 
group.
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of several signs or symptoms (e.g., arthralgia, arthritis, kid-
ney failure, haemolytic anaemia, purpura, Raynaud’s disease 
and paresthesias) related to or present in SLE. 
Patients were divided into three groups as defi ned in 
Table 2, according to the results obtained in the anti-dsDNA 
antibody testing using the two methodologies. The sera from 
Group I belonged to 15 lupus patients. Of these, 12 patients 
had a previous diagnosis of lupus nephritis, one demonstrat-
ed serositis, and another had suffered from SLE for seven 
months, presenting with evidence of positive infl ammatory 
activity, lymphopenia and consumption of the complement 
components C3 and C4. The last patient, who had juvenile 
rheumatoid arthritis (JRA) and had been in treatment for two 
years, tested positive for ANA and anti-dsDNA antibodies in 
this laboratory revaluation nine months before meeting the 
criteria for a diagnosis of SLE. The results of the screening for 
anti-dsDNA antibodies using the CLIA technique in the 15 
sera samples from Group I remained in the 240 IU/mL to 32.6 
IU/mL range with a mean of 167 IU/mL, median of 198 IU/mL 
and mode of 240 IU/mL, and the IFA titres ranged from 1/640 
to 1/20. Eleven sera samples demonstrated readings greater 
than 125 IU/mL in the CLIA and IFA titres of 1/320 or 1/640. 
The values  for the four remaining sera samples (63, 39, 36 
and 32.6 IU/mL) showed titres of 1/320, 1/20 1/160 and 1/320, 
respectively.
The relevant information recorded in the medical records 
of each patient in Group II (clinical condition and laboratory 
changes, with reasons for requesting the anti-dsDNA tests) 
is listed in Table 3. These data showed that 87% (26/30) of 
the cases labelled as false-positive in CLIA had SLE, and 65% 
(17/26) of these patients had a previous diagnosis of lupus ne-
phritis, with a description of signs and/or symptoms of clini-
cal progression of disease in 50% (13) of cases. In addition, iso-
lated laboratory changes compatible with active disease were 
present in 23% (6/26) of patients (cases 5, 8, 11, 19, 25 and 29). 
The results of the anti-dsDNA antibody testing using CLIA 
in Group II (Table 4) was in the range of 184-20 IU/mL, with 
a mean of 59 IU/mL and median 45 IU/mL. Four sera sam-
ples (cases 1 to 4) were positive with values  5 times greater 
than the cut-off point indicated by the manufacturer. Sera 
classifi ed in the ‘grey zone’ accounted for 3.5% (6/169) of the 
sample studied.
The clinical condition of each patient in Group II (Table 
4) was paired with the historic presence of autoantibodies 
and the progression of detection of anti-dsDNA antibodies 
in sera since disease onset. The ANA results were available 
and positive in 97% (29/30) of patients. Anti-Sm antibodies 
were detected in 38% (10/26) of SLE patients in this group. 
A previous history of reactivity to dsDNA (anti-dsDNA by 
IFA) occurred in 50% (13/26) of lupus patients; however, this 
information was not available for two patients from other 
units (cases 25 and 26), and four patients under diagnostic 
investigation were undergoing tests for the fi rst time (cases 
1, 4, 12 and 21). 
Further evaluations of anti-dsDNA antibodies were re-
quested in 77% (23/30) of patients within one year. Among the 
seven remaining patients, three did not have SLE (cases 1, 12 
and 21), three had lupus in clinical and laboratory remission 
(3, 10 and 18) and case number 5, with clinical remission, had 
haematuria at the time of intrinsic validation. 
Two patients (cases 2 and 17) were studied using multi-
ple sera samples. Case 2, which demonstrated a triple posi-
tive evaluation in CLIA (154.6, 46 and 37.5 IU/mL) had been 
diagnosed with SLE and lupus nephritis for four years. This 
patient showed a positive result for anti-dsDNA antibodies 
by enzyme-linked immunosorbent assay (ELISA) (80 U) at the 
onset of the disease (2007), which was not confi rmed by IFA 
in three tests conducted in the 2009 to 2010 period, although 
the IFA test became positive after this patient experienced 
convulsive symptoms for one month. Case 17, which demon-
strated discrepant results in the CLIA (32 and 13.8 IU/mL), had 
been diagnosed with SLE and lupus nephritis 2 months prior, 
although anti-dsDNA results using both CLIA and IFA for this 
patient remained negative after six months. 
Ten patients became reactive by IFA within one year of 
their fi rst evaluation (cases 2, 9, 23 and 26 up to 3 months; 
case 29 after fi ve months; cases 14 and 15 after 9 months and 
cases 7, 20 and 22 after an interval of 12 months). 
The remainder of the sample (Group III) consisted of 58% 
(56/97) of the total number of patients with SLE, 95% (52/55) 
of the patients being tested for autoimmune diseases and the 
majority (94%, 16/17) of patients affected by other autoim-
mune diseases. There were seven duplicate samples in the in-
trinsic evaluation of this group that belonged to fi ve patients 
with SLE, 1 under diagnostic investigation and one with rheu-
matoid disease. The CLIA results in Group III showed values  in 
the range of 19 to 0.5 IU/mL (Fig. 1), with a mean of 5.5 IU/mL, 
median of 4 IU/mL and mode of 0.5 IU/mL.
A prior history of reactivity to dsDNA using IFA in all SLE 
patients who participated in the study (n = 97) was investigat-
ed using the medical and/or laboratory records (Table 5), and 
we found that 48% (47/97) of the samples were reactive, with 
fi ve patients in Group I (positive in both methodologies) un-
dergoing anti-dsDNA testing for the fi rst time. Clinical activity 
measured using the Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI) was not available in all records during 
the test request period, which prevented the study of clinical 
progression (periods of disease activity or remission) related 
to the presence of anti-dsDNA antibodies.
Table 2 – Defi nition of strata for analysis (n = 169).
Group Defi nition Stratum n Total
I Samples positive 
in both techniques 
(CLIA and IFA)
SLE 15 15
II Samples positive in 
CLIA and negative in 
IFA (false positives) 
SLE
SLE overlap syndrome
Autoimmune 
thyroiditis 
Investigation of 
autoimmune diseases
24
2
1
3
30
III Samples negative 
in both techniques 
(CLIA and IFA)
SLE
SLE overlap syndrome
Other autoimmune 
pathologies
Investigation of 
autoimmune diseases
53
3
16
52
124
CLIA, chemiluminescent immunoassay; IFA, indirect 
immunofl uorescence assay; SLE, systemic lupus erythematosus.
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Discussion
Currently, the most commonly used techniques for detecting 
anti-dsDNA antibodies are immunoenzymatic assay and IFA, 
the latter being more specifi c and capable of detecting anti-
bodies with moderate and high affi nity related to SLE activity.9 
ELISA-based methods, although quantitative, reproducible 
and automated, exhibit lower precision in terms of clinical 
performance because they detect low-avidity anti-dsDNA 
autoantibodies, which generally have little clinical relevance 
and may be present in other connective tissue diseases, in-
fl ammatory or infectious diseases and in normal subjects.10 
However, in recent years, a new generation of ELISAs for the 
detection of anti-dsDNA antibodies has been introduced into 
the market, and these new reagents provide greater antigen 
purifi cation, making them more selective for the detection of 
intermediate- and high-avidity antibodies.5 The CLIA method 
evaluated in this study is included in this group.
The performance of the CLIA-LIAISON assay in this in-
trinsic evaluation was satisfactory and produced 100% sen-
sitivity, 82% specifi city and 81% effi ciency when compared 
to IFA. This same CLIA reagent has been tested by the Italian 
Society of Laboratory Medicine Study Group on Autoimmune 
Diseases5 in an extrinsic evauation7 with a clinical samples 
from 52 patients with SLE, 28 patients with other connective 
tissue diseases, 36 patients with hepatitis C virus (HCV) and 
24 patients with other acute viral diseases. These authors re-
ported 84.6% sensitivity, 82.9% specifi city and 83.6% effi ciency 
of the method, which is similar to the results obtained in the 
present study, although the difference in sensitivity may be 
attributed to the clinical samples examined. This study also 
analysed the performance of the automated test for the de-
tection of anti-dsDNA antibodies, according to the reality ex-
perienced by the local population, where the majority (57%) of 
patients who undergo this exam have SLE. The Italian study 
also included patients with HCV who eventually had positive 
CLIA testing for anti-dsDNA antibodies.5
The performance of the CLIA test in identifying a negative 
reaction was adequate in this study, with measures of central 
tendency in Group III convergent with values  less than three 
times the maximum negativity suggested by the manufac-
Table 3 – Relevant information for Group II patients (n = 30)
Pat. G Age Reasons for requesting 
anti-dsDNA test
Time Current condition
Clinical Laboratory changes
1 F 35 Undefi ned arthralgia 1 y under investigation ANA-reactive
2 F 25 SLE + nephritis 4 y activity (convulsion) lymphopenia, Ļ C ', proteinuria
3 F 60 SLE 15 y remission no change
4 F 34 Additive polyarthritis 2 y under investigation ANA-reactive
5 F 33 SLE + nephritis 11 y remission haematuria ++
6 F 21 SLE + nephritis 7 m activity ĻC', haematuria, proteinuria
7 F 24 Mucocutaneous SLE 2 m remission no change
8 F 57 SLE 22 y remission lymphopenia 
9 F 28 SLE + nephritis 5 y activity anaemia, ĻC', proteinuria
10 F 18 SLE + nephritis 2 y remissiona no change
11 F 49 SLE 5 y remission CRP+, ĻC3
12 F 49 Autoimmune thyroiditis 3 y arthralgia haematuria +
13 F 33 SLE + nephritis 8 y activity lymphopenia, Ļ C ', haematuria
14 F 22 SLE 10 m remission no change
15 M 13 SLE 2 m activity ĻC'
16 F 43 SLE + nephritis 5 y activity lymphopenia, haematuria, proteinuria
17 F 34 SLE + nephritis 2 m activity lymphopenia, ĻC', ESR and CRP, 
haematuria, proteinuria
18 F 27 SLE + DM/DP 4 y remission CRP
19 F 14 Mucocutaneous SLE 5 m remission ĻC'
20 F 27 SLE + nephritis 6 y activity ĻC', proteinuria
21 F 49 Undefi ned kidney failure 1 m under investigation proteinuria
22 F 22 SLE + nephritis 4 y activitya haematuria, proteinuria
23 F 23 SLE + nephritis 7 y activitya proteinuria
24 F 28 SLE + nephritis 3 y activitya haematuria, proteinuria
25 F 19 SLE + nephritis 5 y remission lymphopenia 
26 M 34 SLE + nephritis 3 y activitya, haemodialysis ĻC', haematuria, proteinuria, 
creatinine
27 F 46 SLE + nephritis 5 y activitya leukocyturia
28 F 29 SLE + nephritis 18 m activity, haemodialysisb ĻC3, proteinuria, leukocyturia
29 F 61 SLE + SS 10 y remission lymphopenia, ĻC', 
30 F 22 SLE + nephritis 3 y evaluation after 
pregnancy
no change
Pat, patient; G, gender; F, female; y, year; ANA, antinuclear autoantibody; SLE, Systemic lupus erythematosus; C’, complement; m, month; CRP, 
C-reactive protein; M, male; ESR, erythrocyte sedimentation rate; DM/DP, dermatomyositis/dermatopolymyositis; SS, systemic sclerosis
a In the presence of pulse therapy with methylprednisolone and cyclophosphamide.
b Use of rituximab in previous year. 
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Table 4 – Presence of autoantibodies in the serum of Group II patients (n = 30).
 Pat. Current clinical 
condition
Previous history of other 
autoantibodies 
Anti-dsDNA history
Previous Current Later evaluations
(IFA) CLIA (IU/mL) CLIA (IU/mL) IFA (titre)  (interval)
1 Investigation ANA tnc 183.5 tnc tnc  -
2 Activity ANA NR 154.6 49.0 1:80 1 m
3 Remission ANA R 134.1 tnc tnc  -
4 Investigation ANA, Cardio G and M tnc 125.5 tnc NR 5 m
5 Remission ANA, Sm, Cardio G and M R 111.1 tnc tnc  -
6 Activity ANA, Sm, RNP NR 92.5 199.9 NR 10 m
7 Remission ANA NR 92.1 54.1 1:80 12 m
8 Remission ANA R 85.6 19.0 tnc 5 m
9 Activity ANA, Ro, La NR 84.6 189.3  1:320 3 m
10 Remissiona ANA R 68.6 tnc tnc  -
11 Remission ANA, Sm R 51.5 96 e 15.2 NR 2 e 6 m
12 Investigation ANA, Ro tnc 50.9 tnc tnc  -
13 Activity ANA, Sm NR 49.5 38. 2 e 52 NR  3 e 12 m
14 Remission ANA NR 45.2 45.1 1:160 9 m
15 Activity ANA, Sm, Ro NR 44.9 26.7 1:80 9 m
16 Activity ANA, Ro, La R 36.1 4.75 tnc 12 m
17 Activity ANA NR 32.0 12.5 NR 6 m
18 Remission ANA R 31.4 tnc tnc  -
19 Remission ANA, Sm, Cardio G tnc 31.1 28.4 NR 3 m
20 Activity ANA, Sm, RNP R 30.2 45.7 1:80 12 m
21 Investigation tnc tnc 28.7 tnc tnc  -
22 Activitya ANA R 26.6 33.6 1:40 12 m
23 Activitya ANA R 26.5 34.4 1:160 1 m
24 Activitya ANA, Sm, RNP, anti-p NR 25.4 tnc NR 2 m
25 Remission un un 22.7 22.2 NR 10 m
26 Activitya ANA, Ro, Cardio G un 22.1 56.3 1:40 2 m
27 Activitya ANA, RNP R 22.0 45.6 NR 2 m
28 Activity ANA, Sm, Cardio G NR 20.9 8.33 tnc 10 m
29 Remission ANA, Sm, RNP R 20.6 32.5 1:40 5 m
30 Remission ANA R 20.3 18.3 tnc 11 m
Pat, patient; IFA, indirect immunofl uorescence assay; CLIA, chemiluminescent immunoassay; ANA, antinuclear autoantibody; tnc, test not 
conducted; NR, non-reactive; m, month; R, reactive; Cardio G, anticardiolipin G; Cardio M, anticardiolipin M; Sm, anti-Sm; RNP, anti-RNP; Ro, 
anti-SSA(Ro); La, anti-SSB(La); un, evaluation unknown; anti-p, anti-ribossomal p.
a In the presence of pulse therapy with methylprednisolone and cyclophosphamide, anti-ribosomal p.  
Table 5 – Previous history of anti-dsDNA (IFA) in lupus 
patients (n = 97).
Group Reactive Non-
reactive
1st time UN Total
I 10 0 5 0 15
II 13 10 1 2 26
III 19 32 5 0 56
Total 42 42 11 2 97
un, evaluation unknown.
Fig. 1 – Frequency of CLIA results (IU/mL) in Group III 
(n = 124).
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turer (up to 19 IU/mL). In addition, the low frequency (3.5%) 
of grey zone results enabled a clear defi nition of the positiv-
ity of the method. The identifi cation of patients who consti-
tuted Group III demonstrated the specifi city for anti-dsDNA 
antibodies used in the test; of the 45 CLIA-reactive sera, 91% 
(41/45) were from SLE patients.
The availability of the clinical samples also facilitated 
qualitative analysis of the type of patient who receives 
anti-dsDNA testing in the hospital, and these results re-
vealed a clinical and epidemiological profile similar to that 
found in the pathology of lupus where this autoantibody 
is prevalent.11 The vast majority of patients were female 
and in the young adult age range (20-39 years), with the 
Rheumatology Unit accounting for over 70% of the test 
requests. The low prevalence of children and adolescents 
may be explained by the hospital’s focus on the tertiary 
care of adults.
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After the establishment of automated screening for anti-
dsDNA antibodies, positive samples and those with results in 
the grey zone in CLIA were tested by IFA, using Crithidia luciliae 
as a substrate. The implementation of this routine led to the 
optimisation of time and laboratory personnel,6 reducing the 
requirement for manual procedures by more than 70% and 
also reducing the likelihood of procedural and random errors 
that could compromise the quality and accuracy of the re-
leased tests. The potential for cost reduction with this new 
detection approach will be analysed in a subsequent study. 
International trials recommend the use of automated 
reagents for the detection of anti-dsDNA antibodies,3,12-15 al-
though the gold standard method in clinical and laboratory 
research remains IFA.12,16 Because the array of laboratory 
methods for the detection of anti-dsDNA antibodies is con-
tinuously increasing, tests traditionally used in routine work 
are still far from becoming standardised and widely accepted. 
Moreover, physicians should be aware that the agreement 
rates between laboratories, the interpretation of results and 
the diagnostic accuracy are dependent on the analytical vari-
ability and the population of patients being studied.17 In the 
present study, the technical laboratory conditions and the re-
ferral of patients’ serum samples were maintained within the 
normal working routine of the institution. 
This study demonstrated that screening of anti-dsDNA au-
toantibodies using CLIA is a safe (100% sensitivity) and rapid 
method that could improve the quality of tests available to pa-
tients. Among the study fi ndings, it should be noted that most 
of the CLIA results labelled as false positives belonged to lupus 
patients with clinical and/or laboratory disease activity, some 
of whom were confi rmed months later as positive by IFA.
Confl icts of interest
The authors declare no confl icts of interest.
R E F E R Ê N C I A S
1. Ghirardello A, Villalta D, Morozzi G, Afeltra A, Galeazzi M, 
Gerli R, et al. Diagnostic accuracy of currently available 
anti-double-stranded DNA antibody assays. An Italian 
multicentre study. Clin Exp Rheumatol. 2011;29(1):50-6.
2. Heidenreich U, Mayer G, Herold M, Klotz W, Al-Jazrawi SK, 
Lhotta K. Sensitivity and specifi city of autoantibody tests 
in the differential diagnosis of lupus nephritis. Lupus. 
2009;18(14):1276-80.
3. Lemarié R, Jacomet F, Goutte B, Bonnafoux C, Tridon A, 
Evrard B. The anti-dsDNA antibodies: validation of an 
original two step strategy of detection. Ann Biol Clin (Paris). 
2011;69(1):47-53.
4. Launay D, Schmidt J, Lepers S, Mirault T, Lambert M, Kyndt 
X, et al. Comparison of the Farr radioimmunoassay, 3 
commercial enzyme immunoassays and Crithidia luciliae 
immunofl uorescence test for diagnosis and activity 
assessment of systemic lupus erythematosus. Clin Chim 
Acta. 2010;411(13-14):959-64.
5. Antico A, Platzgummer S, Bassetti D, Bizzaro N, Tozzoli 
R, Villalta D. Diagnosing systemic lupus erythematosus: 
new-generation immunoassays for measurement of anti-
dsDNA antibodies are an effective alternative to the Farr 
technique and the Crithidia luciliae immunofl uorescence 
test. Lupus. 2010;19(8):906-12.
6. Meroni PL, Schur, PH. ANA screening: an old test with new 
recommendations. Ann Rheum Dis. 2010;69(8):1420-2.
7. Ferreira AW, Ávila SLM. Diagnóstico Laboratorial das 
principais doenças infecciosas e autoimunes. 2.ed. Rio de 
Janeiro: Guanabara Koogan; 2001.
8. Callado MRM, Vieira RMRA, Araújo VMA, Callado CM, Costa 
Lima JR, Rodrigues JNA, et al. Prevalência dos anticorpos 
antinucleares (ANA) no Hospital Geral de Fortaleza 
no período de jan/2002 a dez/2006. Jornal da Liga dos 
Reumatologistas do Norte-Nordeste (LIRNNE). 2007;3:118-22.
9. Kim KH, Han JY, Kim JM, Lee SW, Chung WT. Clinical 
signifi cance of ELISA positive and immunofl uorescence 
negative anti-dsDNA antibody. Clin Chim Acta. 
2007;380:182–5.
10. Smeenk RJT. Detection of autoantibodies to dsDNA: 
Current insights into its relevance. Clin Exp Rheumatol. 
2002;20:294-300.
11. Pisetsky DS. In: JH, Stone JH, Crofford LJ, White PH (eds.). 
Primer on the Rheumatic Diseases. 13.ed. Springer/
Arthritis Foundation; 2008.
12. Yang JY, Oh EJ, Kim Y, Park YJ. Evaluation of Anti-dsDNA 
antibody tests: Crithidia luciliae immunofl uorescence 
test, immunoblot, enzyme-linked immunosorbent assay, 
chemiluminescence immunoassay. Korean J Lab Med. 
2010;30(6):675-84.
13. Fiegel F, Buhl A, Jaekel HP, Werle E, Schmolke M, Ollert M, et 
al. Autoantibodies to double-stranded DNA--intermethod 
comparison between four commercial immunoassays and 
a research biosensor-based device. Lupus. 2010;19(8):
957-64.
14. El-Chennawi FA, Mosaad YM, Habib HM, El-Degheidi T. 
Comparative study of antinuclear antibody detection by 
indirect immunofl uorescence and enzyme immunoassay 
in lupus patients. Immunol Invest. 2009;38(8):839-50.
15. Suh-Lailam BB, Chiaro TR, Davis KW, Wilson AR, Tebo AE. 
Evaluation of a high avidity anti-dsDNA IgG enzyme-linked 
immunosorbent assay for the diagnosis of systemic lupus 
erythematosus. Int J Clin Exp Pathol. 2011;4(8):748-54.
16. Chiaro TR, Davis KW, Wilson A, Suh-Lailam B, Tebo AE. 
Signifi cant differences in the analytic concordance 
between anti-dsDNA IgG antibody assays for the diagnosis 
of systemic lupus erythematosus-Implications for inter-
laboratory testing. Clin Chim Acta. 2011;412(11-12):1076-80.
17. Ghirardello A, Villalta D, Morozzi G, Afeltra A, Galeazzi 
M, Gerli R, et al. Evaluation of current methods for the 
measurement of serum anti double-stranded DNA 
antibodies. Ann N Y Acad Sci. 2007;1109:401-6.
